Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for Anaptysbio (ANAB) over the last 10 years, with Sep 2025 value amounting to -$10.4 million.

  • Anaptysbio's Cash from Financing Activities fell 114.59% to -$10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.9 million, marking a year-over-year decrease of 165.63%. This contributed to the annual value of $127.1 million for FY2024, which is 314.27% up from last year.
  • Anaptysbio's Cash from Financing Activities amounted to -$10.4 million in Q3 2025, which was up 79.42% from -$50.5 million recorded in Q2 2025.
  • Anaptysbio's Cash from Financing Activities' 5-year high stood at $251.3 million during Q4 2021, with a 5-year trough of -$50.5 million in Q2 2025.
  • Its 3-year average for Cash from Financing Activities is -$2.0 million, with a median of -$10.4 million in 2025.
  • As far as peak fluctuations go, Anaptysbio's Cash from Financing Activities surged by 199,373.02% in 2021, and later plummeted by 3,223.15% in 2023.
  • Quarterly analysis of 5 years shows Anaptysbio's Cash from Financing Activities stood at $251.3 million in 2021, then slumped by 99.22% to $1.9 million in 2022, then crashed by 364.70% to -$5.2 million in 2023, then spiked by 634.35% to $27.6 million in 2024, then crashed by 114.59% to -$10.4 million in 2025.
  • Its Cash from Financing Activities stands at -$10.4 million for Q3 2025, versus -$50.5 million for Q2 2025 and -$28.6 million for Q1 2025.